NextCure (NXTC) Proxy Filing summary

Executive summary

• Annual meeting scheduled for June 20, 2025, with virtual participation available for shareholders.

• Shareholders are encouraged to review proxy materials and vote by June 19, 2025.

Voting matters and shareholder proposals

• Election of three Class III directors: David Kabakoff, Ph.D., Michael Richman, and Stephen W. Webster, all recommended by the board.

• Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2025.

• Advisory vote on executive compensation (say-on-pay) and on the frequency of future say-on-pay votes.

• Proposal to amend the Certificate of Incorporation to allow a reverse stock split at a ratio determined by the board.

• Authorization to adjourn the meeting to solicit additional proxies if necessary.

Board of directors and corporate governance

• Board recommends all director nominees for election.

• Board retains discretion to determine the reverse stock split ratio if approved.